Aegle Therapeutics
Woburn, US · Delaware corporation · 3 known investors
Find your way into Aegle Therapeutics
598 people in our graph share verified history with the Aegle Therapeutics team — schools, employers, funds. One of them is your warm intro.
Chris Bischoffunlockedknows Shelley A. Hartman · together at Goldman Sachs (overlapped)
.jpg)
×8knows the team · via Goldman Sachs
×3knows the team · via Wellesley College
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
Founders & leadership
SA
Shelley A. HartmaninCo-founder & CEOShelley Hartman is co-founder and CEO of Aegle Therapeutics, a clinical-stage biotech company developing extracellular vesicle therapies. She previously served as chairman and CEO of LifeSync Holdings and CEO of LifeSync Corporation, a medical device company, and worked as a managing director in the investment banking division at Goldman Sachs focused on healthcare.
EV
Evangelos V. BadiavasFounder & Chief Scientific Officer
HK
Heidi KempinskiChief Operational Officer
KM
Kathleen MurphyHead of Clinical Operations
RW
Robert Williamson, Jr.Named on SEC filing
RR
Robert RyanNamed on SEC filing
LM
Leon Moulder, Jr.Named on SEC filing
Board
MT
Mikio TanjiBoard director
EB
DS
David SchimelBoard director
SB
Scott BraunsteinBoard director
LM
Leon MoulderBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$9.2M disclosed across 3 of 4 rounds · 2020–2026
▶$2.3MraisedAug 2026 · 17 investors · BiotechnologyRule 506(b)
▶$2.3MraisedAug 2026 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shelley HartmanExecutive Officer, Director
- Scott BraunsteinDirector
- Leon MoulderDirector
- Evangelos BadiavasDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455.7KraisedMar 2026 · 10 investors · BiotechnologyRule 506(b)
▶$455.7KraisedMar 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Evangelos BadiavasDirector
- Shelley HartmanExecutive Officer, Director
- David SchimelDirector
- Scott BraunsteinDirector
- Leon MoulderDirector
- Mikio TanjiDirector
- Steve O'HaraDirector
- Offering amount
- $700K
- Amount sold
- $455.7K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
▶$6.5MraisedJul 2020 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shelley HartmanExecutive Officer, Director
- Evangelos BadiavasExecutive Officer, Director
- Robert Williamson, Jr.Executive Officer, Director
- David SchimelDirector
- Robert RyanDirector
- Elona BaumDirector
- Leon Moulder, Jr.Director
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Egle Tx14 shared keywordsEgle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Apogee Therapeutics6 shared keywordsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Aeglecap6 shared keywordsAegle Capital, a trade name of Aegle Health Partners, Inc., provides financing for commercial healthcare businesses. The firm focuses on healthcare-sector capital.
Perplexity5 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Aegle Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aegle Therapeutics do?
- Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.
- Who founded Aegle Therapeutics?
- Aegle Therapeutics was founded by Shelley A. Hartman, Evangelos V. Badiavas.
- Who are Aegle Therapeutics's investors?
- Aegle Therapeutics's investors include DEFTA Partners, New World Angels, Ocean Azul Partners.
- How much funding has Aegle Therapeutics raised?
- Aegle Therapeutics has disclosed $9.2M raised across 3 of its 4 known rounds.
- Where is Aegle Therapeutics headquartered?
- Aegle Therapeutics is headquartered in Woburn, US.